Kamada (KMDA) Shares Outstanding (Weighted Average) (2012 - 2026)
Kamada (KMDA) reported Shares Outstanding (Weighted Average) of $70.0 for Q1 2026, down 100.0% on a YoY basis from $15.1 billion in Q1 2025, and down 80.0% quarter-over-quarter from $350.0 in Q4 2025.
Kamada (KMDA) Shares Outstanding (Weighted Average) (2012 - 2026) Analysis & Trends
Kamada has reported Shares Outstanding (Weighted Average) for 15 years, with the latest figure at $70.0 in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 100.0% year-over-year to $70.0; the trailing twelve-month figure through Mar 2026 stood at $70.0 (down 100.0% YoY), and the FY2025 full-year result was $350.0, down 100.0% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $70.0, down from $350.0 in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $15.1 billion in Q2 2025, with the low at $40.0 in Q1 2023.
- Historically, Shares Outstanding (Weighted Average) has averaged $3.6 billion across 5 years, with a median of $350.0 in 2025.
- Annual changes were most pronounced in 2025 — Shares Outstanding (Weighted Average) surged 37684999900.0% — and 2026, when it plunged 100.0%.
- Kamada's Shares Outstanding (Weighted Average) stood at $44.8 million in 2022, then increased by 8.96% to $48.8 million in 2023, then soared by 30675.86% to $15.0 billion in 2024, then plunged by 100.0% to $350.0 in 2025, then tumbled by 80.0% to $70.0 in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $70.0 (Q1 2026), $350.0 (Q4 2025), and $15.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 1.16 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 422.10 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 43.50 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 5.02 Bn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 100.50 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 497.70 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 166.20 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 64.74 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 228.36 Mn |
| 10 | Kamada | 505.05 | -73.15 Mn | 19.12 Mn | 70.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.00 |
| Dec 31, 2025 | 350.00 |
| Sep 30, 2025 | 15.08 Bn |
| Jun 30, 2025 | 15.08 Bn |
| Mar 31, 2025 | 15.07 Bn |
| Dec 31, 2024 | 15.03 Bn |
| Sep 30, 2024 | 190.00 |
| Jun 30, 2024 | 120.00 |
| Mar 31, 2024 | 40.00 |
| Dec 31, 2023 | 48.83 Mn |
| Sep 30, 2023 | 15.02 Mn |
| Jun 30, 2023 | 40.00 |
| Mar 31, 2023 | 40.00 |
| Dec 31, 2022 | 44.82 Mn |
| Sep 30, 2022 | 120.00 |
| Jun 30, 2022 | 130.00 |
| Mar 31, 2022 | 11.73 Mn |
| Dec 31, 2021 | 44.77 Mn |
| Sep 30, 2021 | 11.72 Mn |
| Jun 30, 2021 | 11.72 Mn |